质量(理念)
数据整理
数据科学
数据质量
风险分析(工程)
计算机科学
可靠性(半导体)
真实世界的证据
真实世界数据
最佳实践
产品(数学)
药店
药物开发
过程管理
业务
知识管理
医学
药理学
药品
政治学
营销
功率(物理)
公制(单位)
哲学
内科学
法学
家庭医学
物理
认识论
量子力学
数学
几何学
作者
Cheryl A. Grandinetti,Donna R. R Rivera,Lee H. Pai-Scherf,Anna Choe,Paul Gustav Kluetz,Stefanie Kraus,Gabriel K. Innes,Kassa Ayalew
标识
DOI:10.1007/s43441-025-00791-1
摘要
The increasing use of real-world data (RWD) to generate real-world evidence (RWE) presents unique opportunities and challenges for drug development and regulatory decision-making, particularly in the area of good clinical practice inspections. FDA typically focuses their application review-based inspections on pivotal studies that generate evidence submitted to support new drug and biological product applications. This focus applies regardless of the data sources used in those studies. In this article, we discuss the fundamental role of good clinical practice inspections in verifying the quality, integrity, and reliability of RWD used in regulatory submissions. Through case examples, we highlight specific challenges related to accessing RWD source records, assessing data quality, and evaluating processes for data curation, transformation, and analysis. Our experience underscores the importance of early engagement with regulatory agencies as well as the implementation of robust quality management practices throughout the study lifecycle. As RWD continues to shape the regulatory landscape, these case examples provide insights in navigating the complexities associated with submissions utilizing RWE for drug approval.
科研通智能强力驱动
Strongly Powered by AbleSci AI